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Abstract
Background: Data from interventional trials of systemic anticoagulation for sepsis inconsistently suggest beneficial
effects in case of acute lung injury (ALI). Severe systemic bleeding due to anticoagulation may have offset the
possible positive effects. Nebulization of anticoagulants may allow for improved local biological availability and as
such may improve efficacy in the lungs and lower the risk of systemic bleeding complications.
Method: We performed a systematic review of preclinical studies and clinical trials investigating the efficacy and
safety of nebulized anticoagulants in the setting of lung injury in animals and ALI in humans.
Results: The efficacy of nebulized activated protein C, antithrombin, heparin and danaparoid has been tested in
diverse animal models of direct (for example, pneumonia-, intra-pulmonary lipopolysaccharide (LPS)-, and smoke
inhalation-induced lung injury) and indirect lung injury (for example, intravenous LPS- and trauma-induced lung
injury). Nebulized anticoagulants were found to have the potential to attenuate pulmonary coagulopathy and
frequently also inflammation. Notably, nebulized danaparoid and heparin but not activated protein C and
antithrombin, were found to have an effect on systemic coagulation. Clinical trials of nebulized anticoagulants are
very limited. Nebulized heparin was found to improve survival of patients with smoke inhalation-induced ALI. In a
trial of critically ill patients who needed mechanical ventilation for longer than two days, nebulized heparin was
associated with a higher number of ventilator-free days. In line with results from preclinical studies, nebulization of
heparin was found to have an effect on systemic coagulation, but without causing systemic bleedings.
Conclusion: Local anticoagulant therapy through nebulization of anticoagulants attenuates pulmonary
coagulopathy and frequently also inflammation in preclinical studies of lung injury. Recent human trials suggest
nebulized heparin for ALI to be beneficial and safe, but data are very limited.
Introduction
Pulmonary coagulopathy is intrinsic to acute lung injury
(ALI). Indeed, both microvascular thrombi and alveolar
fibrin depositions are hallmarks of ALI, irrespective of
its cause [1-5]. The extent of pulmonary coagulopathy
depends on the severity of ALI [1] and is clearly linked
to the outcome of ALI [6-9]. Pulmonary coagulopathy
with ALI resembles systemic coagulopathy with sepsis
[4], and is characterized by activated coagulation,
attenuation of fibrinolysis, and enhanced breakdown
and/or decreased production of natural anticoagulants
(Figure 1) [4,10,11]. Extensive cross-talk between coagu-
lation and inflammation may further inflame the lungs
[3]. Indeed, activated coagulation factors may initiate or
exaggerate injury [12-14], impairing alveolar aeration
and perfusion [15], and promoting fibrosis [16].
Clinical trials inconsistently suggest beneficial effects
of systemic anticoagulants in patients with ALI. Results
from the PROWESS trial suggested patients with a pul-
monary cause of their sepsis to benefit more from sys-
temic anticoagulation with recombinant human (rh)-
activated protein C (APC) than patients with sepsis
from another source [17-19]. A recent clinical trial of
patients with ALI even showed decreased pulmonary
dead-space fraction with infusion of rh-APC, although
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this was not associated with an improved clinical out-
come [20]. Notably, rh-APC has been withdrawn from
the market, as the recent PROWESS-SHOCK trials
showed no benefit from rh-APC in patient with septic
shock [21]. Neither infusion of antithrombin (AT) nor
infusion of rh-tissue factor pathway inhibitor (TFPI) has
been found to improve outcome in sepsis [22,23]. Infu-
sion of AT, however, was found to prevent new pul-
monary dysfunction [24]. Infusion of rh-TFPI was
suggested to improve survival of patients with a com-
munity-acquired pneumonia [25] but failed to improve
outcome of patients with severe community-acquired
pneumonia in the recent CAPTIVATE trial [26]. Finally,
post hoc analysis of four large clinical trials of patients
with sepsis suggested infusion of low-dose heparin to
improve survival, although unintended pitfalls may not
have been accounted for [27]. However, one recent clin-
ical trial showed no effect on survival with infusion of
unfractioned heparin [28].
High pulmonary concentrations of an anticoagulant
may be necessary to have any effect on pulmonary coa-
gulation, maybe higher than achievable with systemic
treatment. Similar to systemic antimicrobial therapy for
pneumonia, with which antimicrobial agents penetrate
in dissimilar amounts into the lung [29], it could be
argued that anticoagulants may not penetrate into lung
tissue adequately to have a local effect. A major concern
is the association between systemic anticoagulation and
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Figure 1 Schematic and simplified presentation of coagulation, fibrinolysis and anticoagulant pathways. The coagulation cascade is
started through activation of tissue factor (TF)-factor VII (FVIIa) complex. Several coagulation factors accelerate the conversion of prothrombin to
thrombin. Activated protein C (APC) can inactivate coagulation factors Va and VIIIa. Antithrombin (AT) serves to block the action of multiple
coagulation factors (for example, Xa and IIa). Tissue factor pathway inhibitor (TFPI) inhibits stepwise the activation of coagulation factors. The
fibrinolytic system is designed to degrade clots and fibrin degradation products (FDP) are formed. The main inhibitor of the plasminogen
activators is plasminogen activator inhibitor type 1 (PAI-1). +: stimulating effect; -: inhibiting effect. Adapted and modified from Tuinman et al.
[59].
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the high incidence of serious bleeding complications in
patients with sepsis, which at times could be life-threa-
tening [17,22,23,30,31]. With higher systemic dosages,
possibly necessary to have sufficiently high concentra-
tions in the lung, without doubt the incidence of bleed-
ings would rise.
Local administration of anticoagulants, through nebu-
lization, may allow for higher pulmonary concentrations
while, at the same time, preventing systemic bleedings.
To test the hypothesis whether nebulization of anticoa-
gulants attenuates pulmonary coagulation without hav-
ing systemic side-effects, we searched the literature for
preclinical studies and human trials of nebulized antic-
oagulants in the context of lung injury in animals and
ALI in humans. We aimed to search for any beneficial
and harmful effects of nebulized anticoagulants.
Materials and methods
Data sources
To identify relevant manuscripts on local anticoagula-
tion in the setting of lung injury in animals and ALI in
humans, two search strategies were followed. First, an
electronic search in Medline and Embase databases was
conducted. Second, the reference lists of retrieved
papers were screened for potentially important papers.
The search was limited to papers published from 1980
until now, and papers written in the English language.
Keywords
The Medline database was used to identify medical sub-
ject headings (MeSH) to select search terms. In addition
to MeSH terms, also free text words were used. Search
terms referred to aspects of the condition (’acute lung
injury’ (ALI), ‘acute respiratory distress syndrome’
(ARDS)) as well as related conditions (’pneumonia’, sep-
sis’, and ‘ventilator-induced lung injury’ (VILI)). In addi-
tion, we searched on the intervention (’nebulized’,
‘vaporized’, and ‘aerosolized’), and anticoagulant agents
(’APC’, ‘AT’, ‘TFPI’, ‘heparin’ and ‘danaparoid’). We
chose to limit the search of agents to those that have
been tested in phase III trials of sepsis (rh-APC, AT and
rh-TFPI), and those commercially available and fre-
quently given to critically ill patients (heparin and dana-
paroid). The same search strategy was used in Embase.
A Prisma flow diagram of the applied search strategy
and selection process is summarized in Figure 2.
Study selection
Titles and abstracts of identified manuscripts were
reviewed on:
• Population (that is, animal models of lung injury or
patients with ALI) and the related settings (pneumonia,
sepsis or VILI)
• Intervention (that is, local anticoagulation)
• Outcome (that is, lung injury and inflammation, pul-
monary coagulation, systemic coagulation and bleeding)
In case of uncertainty, the complete manuscript was
obtained and evaluated.
Data extraction
Manuscripts were critically appraised along two research
questions:
• Do nebulized anticoagulants affect pulmonary coagu-
lation, parameters of lung injury, and/or outcome?
• Do nebulized anticoagulants affect systemic coagula-
tion and, as such, cause bleedings?
Results
Preclinical studies of local anticoagulation
The search of preclinical studies of pulmonary anticoa-
gulation yielded 10 preclinical studies of nebulized and
one with intratracheal anticoagulants for lung injury
with a large diversity in outcome measures (Table 1).
Four preclinical studies tested nebulized rh-APC
[32-35], four studies compared rh-APC, plasma-derived
human AT, heparin and danaparoid [36-39], one study
tested heparin [40], one study compared nebulized
heparin with systemic infusion of heparin [41], and one
study compared nebulized heparin with systemic infu-
sion of heparin and lisofylline (LSF) [42]. The search did
not yield any preclinical study that investigated the
effects of nebulized rh-TFPI.
Recombinant human-activated protein C
Although in none of the preclinical studies pulmonary
levels of rh-APC were measured, nebulization of rh-
APC was found to attenuate activation of pulmonary
coagulation [34,36,37], and to stimulate pulmonary fibri-
nolysis [36]. Nebulization of rh-APC inconsistently
reduced pulmonary inflammation [34-36]. Furthermore,
nebulization of rh-APC was found to improve oxygena-
tion [32,34,35], and to reduce histolopathological
derangements [32,34,35]. While nebulization of rh-APC
improved aerated lung volume, it had no effect on extra-
vascular lung water (EVLW) [33]. Nebulization of rh-
APC has neither been associated with systemic coagula-
tion [33] nor with signs of systemic bleeding [36].
Dosages and timing of rh-APC varied amongst studies:
from five times 48 μg/kg [33] up to 200 mg/kg as a sin-
gle dose [35].
Plasma-derived human antithrombin
Nebulization of plasma-derived AT was found to
increase pulmonary levels of AT [36,37], to attenuate
activation of pulmonary coagulation [36,37] and to sti-
mulate pulmonary fibrinolysis [36]. Alike with rh-APC,
nebulized plasma-derived AT inconsistently reduced
pulmonary inflammation [36,38]. Furthermore, nebuliza-
tion of plasma-derived AT was found to reduce histo-
pathological derangements and bacterial outgrowth in
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models of infectious lung injury [36]. Nebulization of
plasma-derived AT has not been associated with an
affect on systemic coagulation [36,37]. Dosages of
plasma-derived AT varied amongst studies: from 10 IU/
kg [38] to as high as 500 IU/kg [36,37].
Heparin
Nebulization of heparin and intratracheal-installed
heparin were found to attenuate pulmonary
coagulopathy [36,37,40]. Nebulization of heparin, as
expected, was not found to affect fibrinolysis
[36,37,40]. Intratracheal-installed heparin reduced pul-
monary inflammation and endothelial permeability. In
addition intratracheal-installed heparin improved survi-
val, reduced bacterial outgrowth and bacterial adher-
ence to lung epithelium [40]. Nebulization of heparin
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Figure 2 Prisma flow diagram showing the search strategy and selection process.
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Furthermore, nebulization of heparin did affect sys-
temic coagulation [37]. The dosages of heparin varied
between an estimated 333 IU/kg [38,39,41,42] and
1000 IU/kg [36,37].
Danaparoid
Nebulization of danaparoid was also found to attenuate
pulmonary coagulopathy but not fibrinolysis [36,37].
Danaparoid reduced local coagulation, but not
Table 1 Animal models of acute lung injury evaluating the effects of treatment with local anticoagulant therapy.
Drug (dose) Animal Lung injury model
and nebulizer
Effect parameter, observed effect and safety Reference
Rh-APC (12.5 μg/h) mice Mechanical ventilation
Aeroneba
Rh-APC attenuated pulmonary inflammation, improved
oxygenation, and prevented endothelial dysfunction.
Rh-APC did not increase pulmonary bleeding.
Maniatis
[32]
Rh-APC (48 μg/kg/h) sheep i.v. LPS
Servo Ultrab
Rh-APC improved oxygenation and increased aerated lung
volume; EVLW was unaffected.
Rh-APC did not cause systemic bleeding.
Waerhaug
[33]




Rh-APC attenuated pulmonary coagulation and
inflammation; Rh-APC improved lung function.
No differences between single and repeated dosing.




Rh-APC (4 mg/3 mL) mice i.t. LPS
DeVilbissc
Rh-APC attenuated pulmonary inflammation, decreased
VCAM-1 upregulation and prevented changes in
histopathology.












All agents attenuated pulmonary coagulation.
Plasma-derived human AT also attenuated pulmonary
inflammation, bacterial outgrowth and changes in
histopathology.
Only danaparoid affected systemic coagulation. Systemic










All agents attenuated pulmonary coagulation; pulmonary
inflammation and histopathology were not affected.
Heparin and danaparoid affected systemic coagulation.
Systemic bleeding was not reported
Hofstra
[37]
Heparin (5 μg) i.t. mice Legionella
pneumonia
No nebulizer used
Heparin improved survival and decreased pulmonary
inflammation, bacterial outgrowth, Legionella adherence
and endothelial permeability.








sheep burn and smoke
inhalation
Nebulizer not stated
Combination therapy improved hemodynamics and P/F
ratio; airway obstruction and wet-to-dry weight decreased.




Combination therapy of Heparin (10,000
IU/4 h) and plasma-derived human AT i.
v. (0.34 mg/kg/h)
sheep burn and smoke
inhalation
Nebulizer not stated
Heparin + plasma-derived human AT improved P/F ratio;
central venous pressure, airway obstruction and wet-to-dry
weight decreased.












Nebulization of heparin improved hemodynamics and P/F
ratio; airway obstruction, wet-to-dry weight and changes in
histopathology were decreased.
Systemic clotting time was unaffected with nebulized







(10 mg/kg/h after bolus 20 mg/kg)
sheep burn and smoke
inhalation
Nebulizer not stated
Combination therapy decreased the need of mechanical
ventilation, P(A-a)O2 and pulmonary shunt fraction; wet-to-
dry weight and changes in histopathology were
unaffected.




Drugs delivered intravenously (i.v.) and intratracheally (i.t.) are described in the table See original manuscript for details. aAerogen, Galway, Ireland. bSiemens-
Elema AB, Solna, Sweden. cHealth Care Worldwide, Somerset, PA, USA. dAllegiance Healthcare, McGaw Park, IL, USA. AT, antithrombin; EVLW, extravascular lung
water; LPS, lipopolysaccharide; P/F, PaO2/FiO2; Rh-APC, recombinant human-activated protein C; VCAM-1, vascular cell adhesion molecule 1
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inflammation [37]. Danaparoid was found to have an
effect on systemic coagulation [36,37]. A dose of 250 E/
kg was used in both studies.
Combined therapies
Combined nebulization of AT or systemic infusion of
AT with nebulization of heparin was found to reduce
wet-to-dry lung weight ratios and airway obstructions,
and to improve lung function [38,39]. Combined nebuli-
zation of heparin and systemic lysofylline was found to
reduce need for mechanical ventilation, to decrease pul-
monary shunt fraction, but not to reduce wet-to-dry
lung weight ratios [42]. Combined nebulization of
heparin and AT was not found to affect clotting times
[38,39].
Clinical trials of nebulized anticoagulants
The search did not yield any clinical trial that investi-
gated the effects of nebulization of rh-APC, plasma-
derived human AT or rh-TFPI; three trials tested the
nebulization of heparin (Table 2).
Heparin
In a phase I trial of patients with ALI, heparin was neb-
ulized at different dosages, namely 50,000 U/day,
100,000 U/day, 200,000 U/day or 400,000 U/day for two
days. An Aeroneb Pro (Aerogen, Galway, Ireland) vibrat-
ing mesh nebulizer was used in this study. Sixteen
patients were enrolled with a mean age of 58 years.
Patients were ventilated in a pressure-support mode of
ventilation and peak airway pressures were maintained
below 35 cm H2O. Nebulization of heparin partly pre-
vented activation of coagulation, evidenced by a reduc-
tion of thrombin-antithrombin complexes and fibrin
degradation products in the broncheoalveolar lavage
fluid, but lung function remained unchanged. With
higher dosages, nebulization of heparin was found to be
associated with an increase of systemic activated partial
thromboplastin time (APTT) [43,44], without causing
systemic bleedings.
In a single-center, retrospective case-control study of
30 patients with smoke inhalation-associated ALI, cases
were compared with historical controls. All patients
were ventilated with volume-cycled ventilation at a tidal
volume of 5 to 8 ml/kg. The peak airway pressures were
maintained below 40 cmH2O. The dose of nebulized
heparin used was 10,000 U every four hours for seven
consecutive days. Nebulization of heparin combined
with N-acetylcysteine and albuterol sulfate was asso-
ciated with an improved survival and improved lung
injury scores (LIS) [45]. No data on pulmonary coagula-
tion or inflammation and nebulizer used were reported.
In a randomized controlled trial of 50 patients who
were expected to require mechanical ventilation for
more than 48 hours’ treatment with 25,000 U of heparin
for six times a day, with a maximum of 14 days, was
compared to placebo [15]. An Aeroneb Pro vibrating
mesh nebulizer was used in this study. Of note, pulmon-
ary levels of coagulation and inflammation were not
affected. No difference in bleeding events was observed
between groups, even in patients with co-administrated
systemic heparin, but APTT levels were higher in the
intervention group. No effect on mortality was seen, but
treatment with heparin was associated with fewer days
of mechanical ventilation (MV) and a trend for a higher
PaO2/FiO2 (P/F) ratio.
Discussion
Ten years ago, to many in the pulmonary or critical care
community the idea that anticoagulants could be a ben-
eficial therapy in ALI may have been surprising and the
approach unfamiliar [46]. Nowadays, several preclinical
and clinical trials have been conducted with anticoagu-
lants in the setting of experimental lung injury in
Table 2 Human models of acute lung injury evaluating the effects of treatment with nebulized anticoagulant therapy.
Drug Model, design, dose and
nebulizer
Effect parameter, observed effect and safety Reference
Heparin RCT of 50 patients expected to
need
> 48 hours of MV
25,000 U 6 dd for 14 days
Aeroneb Proa
Heparin increased the number of ventilator-free days; P/F ratio and mortality were
unaffected. There was a trend for less tracheotomies with heparin.








Case control study of 30
patients after smoke inhalation
10,000 U 6 dd for 7 days
Nebulizer not stated
Heparin + acetylcysteine + albulterol improved survival and lung injury score.
Effects on systemic coagulation and systemic bleeding were not reported.
Miller
[45]
Heparin Phase 1 trial of 16 patients with
ALI
50-400 × 103 U/day for 2 days
Aeroneb Proa
Heparin attenuated pulmonary coagulation; P/F ratio and lung compliance were not
affected.
Heparin increased APTT. The incidence of systemic bleedings was not affected.
Dixon
[43,44]
See original manuscript for details. aAerogen, Galway, Ireland. ALI: acute lung injury; APTT, activated partial thromboplastin time; MV, mechanical ventilation; RCT,
randomized controlled trial.
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animals or ALI in humans. The clinical evidence for
pulmonary anticoagulant therapy is severely limited,
since only one randomized controlled trial has been per-
formed. The identified preclinical studies all showed
clear evidence for attenuating effects of nebulized antic-
oagulants on local coagulation, a phenomenon that has
been associated with morbidity and mortality of ALI.
Given the extensive crosstalk between inflammation and
coagulation [47], the observed diminishing effects on
local coagulation may be countable for dampened pul-
monary inflammation with nebulization of
anticoagulants.
It should be noted that while rh-APC and rh-TFPI
were infused in a continuous fashion in clinical trials of
sepsis [17,23,30,31,48,49], in the reviewed preclinical
studies these anticoagulants were nebulized intermit-
tently. Although half-life of rh-APC in plasma is short
[50], rh-APC could be detected in mice bronchoalveolar
lavage fluid up to 24 hours after inhalation [51]. It is
uncertain whether continuous nebulization would
improve the pulmonary effects of rh-APC, but consider-
ing longer bioavailability and intermittent dosing, local
administration may affect both efficacy and costs.
Nebulization of rh-APC or plasma-derived human AT
did not affect systemic coagulation, suggesting local
administration of these agents to be safe and, as such, to
have a potential benefit over systemic administration.
Nebulization of heparin or danaparoid, however, did
affect systemic parameters of coagulation. These agents
seem to have the potential to leak from the pulmonary
compartment into the circulation [36,37]. This may not
come as a surprise, since both heparin and danaparoid
are relatively small molecules (8 and 5.5 kDa respec-
tively), much lower than APC and AT (56 and 58 kDa
respectively). Of note, in a phase I trial, nebulization of
heparin in a high dosages lengthened clotting time only
after > 24 hours [43], suggesting that heparin may be
stored and metabolized in pulmonary endothelial cells,
initially limiting heparin from reaching the systemic cir-
culation. Notably, the results from the clinical trials of
nebulization of heparin showed no increase on systemic
bleedings.
Five major variables influence local drug delivery in
the lung during mechanical ventilation, that is, the aero-
sol generator, aerosol particle size, conditions in the
ventilatory circuit, artificial airway and ventilator para-
meters [52]. Unfortunately, most of these variables were
insufficiently addressed in the retrieved studies. In addi-
tion, different types and brands of nebulizers were used,
including jet [35,41], ultrasonic [33] and vibrating mesh
nebulizers [34,36,37]. Some studies did not report which
nebulizer was used [38,39,42]. No studies mention the
particle size delivered by the used nebulizer and prob-
able losses of study drug, which would have been of
interest, since it is one of the determinants of drug
delivery to the lungs [52]. In addition, maldistribution of
nebulized drugs to areas of better ventilation away from
areas of collapse and consolidation is a concern of nebu-
lized agents. After nebulization, uptake through the
bronchial mucosa and distribution by a rich network of
submucosal capillaries to other areas of the lung, could
lead to adequate concentrations at various sites in the
lung, as seen with inhaled antibiotics [53]. Another
potential risk is that with higher local concentrations of
anticoagulants in the lung, systemic measures of antic-
oagulation may not measure local bleeding risk. These
aspects need further attention in future studies.
A potential harm from local anticoagulant therapies
lies in the fact that part of the procoagulant response
may be needed for healing. Notably, coagulation and the
formation of fibrin are natural responses to injury. The
coagulation system may play a role in containing patho-
gens to the side of infection [54]. In a model of Pseudo-
monas pneumonia, interfering with the initial
procoagulant response showed to be a potentially dan-
gerous strategy, since it was associated with increased
bacteremia [55,56]. In the studies identified by our
search, no increased spread of bacteria was observed,
though. On the other hand, anticoagulants may also
have beneficial antimicrobial effects. Indeed, local
heparin has been shown to have an anti-adherence
effect, making it, for Legionella pneumophila, unable to
adhere to airway epithelial cells in the alveolar space
[40]. Also, AT has been shown to limit bacterial out-
growth of Streptococcus pneumoniae in a rat model of
pneumonia with this pathogen [36]. Thus, anticoagu-
lants could also act as an adjuvant to conventional anti-
microbial therapy in patients who are mechanically
ventilated.
Our search identified only three trials of local anticoa-
gulants in patients [15,43,45]. The trial of patients who
needed prolonged mechanical ventilation knows several
potential weaknesses. The population was very heteroge-
neous, since it included unselected patients requiring
mechanical ventilation beyond 48 hours, independent of
the reason. Furthermore, a large proportion of patients
received systemic heparin (24 versus 32%, in heparin-
treated and control patients respectively). Finally, it
should be mentioned that this trial was performed in a
single ICU.
Investigations in animals and patients with burns and
smoke inhalation and burns are a distinct category,
since this insult is characterized by massive airway
obstructive casts [38], resulting in atelectasis, air trap-
ping, alveolar hyperinflation and barotraumas, and
maybe even pneumonia [39,57,58]. The effects of nebu-
lized anticoagulants on cast formation may not be com-
parable to the anticoagulant effects of these agents in
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ALI by another cause. One major weakness of the clini-
cal trial that showed beneficial effects of nebulized
heparin in these patients is that historic controls were
used [45]. Furthermore, side-effects were not reported.
Due to the marked differences in study design and
patient characteristics, the cumulative summary of these
data should be interpreted with caution. But this preli-
minary analysis, despite a number of caveats, suggests
further studies to be undertaken. We are in need of
more animal studies and clinical trials that address the
promising concept of administration of anticoagulants
to the lungs. We favor mechanistic studies before rando-
mized controlled trials for several reasons. First, dosages
were arbitrarily chosen in most preclinical studies. Sec-
ond, assessment of distribution of inhaled anticoagulants
in the lungs and its final (plasma) concentrations have
to be better addressed. While larger agents may have
limited access to the lower airways, smaller agents may
leak more easily into the systemic circulation. Third,
animal models of pneumonia should mimic as much as
possible the clinical scenario and as such, should
include, for instance, the use of antibiotics.
Conclusions
Preclinical studies in models of lung injury show nebuli-
zation of anticoagulants to reduce pulmonary coagulo-
pathy and inflammation. Neither nebulized APC nor
nebulized AT affects systemic coagulation, whereas
heparin and danaparoid do affect systemic coagulation.
Initial clinical trials of nebulized heparin show beneficial
effects in ALI.
Key messages
• Nebulization of anticoagulants attenuates pulmonary
coagulopathy and pulmonary inflammation
• Neither nebulized APC nor nebulized AT affect sys-
temic coagulation, whereas heparin and danaparoid do
affect systemic coagulation
• Nebulization of heparin improves survival in patients
with smoke inhalation-associated ALI
• Nebulization of heparin reduces the days of mechan-
ical ventilation in patients with prolonged need for
mechanical ventilation
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